U87 Orthotopic Mouse Model Service for Brain Cancer

The U87 orthotopic mouse model for brain cancer provides the most widely utilized human glioblastoma xenograft platform, distinguished by its PTEN-null genomic background, p53-wild-type apoptotic competence, MGMT-methylated temozolomide sensitivity, and robust VEGF-driven angiogenesis—offering a predictable, high-throughput system for evaluating targeted therapies and blood-brain barrier penetration. Alfa Cytology delivers this specialized orthotopic model service with integrated capabilities spanning STR-authenticated cell expansion, stereotactic intracranial implantation into immunodeficient hosts, longitudinal bioluminescence and MRI monitoring, and comprehensive vascular and molecular endpoint analysis—empowering researchers to generate reproducible preclinical data for their glioblastoma therapeutic pipeline.

Overview of U87 Orthotopic Mouse Model for Brain Cancer

The U87MG cell line was originally established in 1966 at Uppsala University from a surgical specimen of a 44-year-old female patient diagnosed with malignant glioma, and is catalogued as ATCC HTB-14. Decades of genetic characterization have revealed that the currently distributed U87MG cells carry a homozygous deletion of the PTEN tumor suppressor gene, resulting in constitutive activation of the PI3K/Akt pro-survival pathway. In contrast to many glioblastoma lines, TP53 remains wild-type, preserving p53-mediated apoptotic signaling and rendering the model responsive to MDM2 antagonists and DNA-damage-inducing agents. The line also exhibits MGMT promoter methylation with consequent loss of MGMT protein expression, conferring marked sensitivity to alkylating agents such as temozolomide. Cytogenetically, U87MG displays a hyperdiploid karyotype with numerous chromosomal abnormalities, including deletions at the CDKN2A locus, consistent with common alterations in human glioblastoma. Histologically, the cells have lost the astrocytic identity of the original tumor, showing minimal glial fibrillary acidic protein (GFAP) expression in vitro and in vivo, yet they retain robust proliferative capacity and strong tumorigenic potential.

Fig 1. U-87 MG in situ model brain slices H&E (A: 1×10⁴, B: 1×10⁵, C: 3×10⁵, arrow indicates tumor) and tumor volume quantification (D). (Kim, Woong, et al., 2015)

When implanted orthotopically into the striatum of immunodeficient mice, U87MG cells form well-circumscribed, non-infiltrative intracranial tumors with a compact growth pattern and sharply demarcated borders—a phenotype that differs from the diffuse invasion of patient glioblastomas yet offers distinct experimental advantages. The tumors are highly vascularized, featuring large, dilated vessels throughout the mass and elevated vascular endothelial growth factor (VEGF) production driven by PTEN loss. This pronounced angiogenic profile, combined with an extensively disrupted and hyperpermeable blood-brain barrier characterized by PLVAP-positive fenestrated endothelium, makes the U87 orthotopic model particularly valuable for evaluating anti-angiogenic agents, nanoparticle-based drug delivery systems, and therapies targeting the PI3K/Akt axis. The predictable tumor kinetics and 100% engraftment rate further position U87MG as a cornerstone model for early-stage preclinical pharmacology and intracranial drug distribution studies.

Cell Line Information: U87

The table below presents comprehensive characterization data for the U87MG human glioblastoma cell line to support model selection and experimental design for preclinical brain cancer studies.

Our Services

Alfa Cytology provides a comprehensive U87 orthotopic mouse model service tailored to the demands of vascular and pathway-targeted glioblastoma preclinical research, encompassing STR-authenticated cell expansion, precision stereotactic intracranial implantation into nude or NSG hosts, longitudinal bioluminescence and MRI tumor tracking, and detailed histopathological, vascular, and PI3K/Akt endpoint characterization. Our neuro-oncology team ensures reproducible tumor kinetics, stringent quality control, and flexible study architectures that integrate seamlessly with your therapeutic development objectives.

Workflow of U87 Orthotopic Mouse Model Construction

Construction of the U87 orthotopic glioblastoma model employs a refined stereotactic neurosurgical protocol optimized for this classic human xenograft line, ensuring high engraftment fidelity, minimal perioperative morbidity, and consistent intracranial tumor progression with predictable vascularized growth. The workflow integrates cell quality verification, precision intracranial delivery, and longitudinal multimodal monitoring to generate robust, publication-quality preclinical datasets.

1. Cell Line Authentication and Expansion: U87MG cells are authenticated by human STR profiling and expanded in high-glucose DMEM complete medium to ensure PTEN-null phenotype stability, hyperdiploid karyotype integrity, and viability >95% prior to surgical preparation.
2. Luciferase Labeling (Optional): For longitudinal non-invasive monitoring, U87MG cells are transduced with a luciferase reporter construct and selected to generate stable pools with high bioluminescent signal output suitable for real-time intracranial growth tracking.
3. Host Selection and Acclimatization: Immunodeficient mice—typically female athymic BALB/c nude mice or NOD/SCID mice aged 6–8 weeks—are acclimatized for at least one week with health screening and baseline body weight recording to minimize inter-animal variability.
4. Anesthesia and Surgical Preparation: Mice are anesthetized with isoflurane (induction 2.5%, maintenance 1–2%) or pentobarbital sodium; the head is shaved, disinfected with alternating betadine and alcohol swabs, and secured in a stereotactic frame with a thermoregulated heating pad.
5. Stereotactic Coordinate Calibration: Bregma and lambda are identified after gentle periosteal reflection; a 0.9 mm burr hole is drilled at coordinates 1.8 mm lateral and 0.6 mm anterior to bregma, targeting the right corpus striatum at a depth of 3.0 mm, with the dura mater left intact to minimize cortical trauma.
6. Intracranial Cell Injection: A Hamilton syringe loaded with 5 µL of U87MG cell suspension (1 × 10⁵ viable cells in sterile PBS) is inserted to the target depth, and cells are slowly injected at a controlled rate over 3–5 minutes; the needle is held in place for 3–5 minutes to prevent reflux along the injection tract.
7. Cranial Closure and Postoperative Care: The burr hole is sealed with bone wax or sterile collagen sponge, the scalp incision is closed with surgical adhesive or sutures, and mice are recovered on a heated pad with analgesic support per institutional animal care guidelines.
8. Tumor Establishment Verification: Tumor engraftment is confirmed 7–14 days post-implantation via bioluminescence imaging (for luciferase-expressing lines) or T2-weighted MRI; mice displaying confirmed tumor signals are randomized into vehicle and treatment cohorts.
9. Longitudinal Monitoring and In-Life Assessment: Tumor burden is tracked weekly via bioluminescence imaging and T2-weighted MRI; concurrent recording of body weight, neurological deficit scoring, and overall clinical condition enables early detection of treatment-related toxicities and peritumoral edema.
10. Treatment Administration: Investigational agents—including PI3K/Akt pathway inhibitors, VEGF/VEGFR blockers, temozolomide and alkylating-agent analogs, MDM2 antagonists, nanoparticle-based delivery systems, or combination regimens—are administered according to protocol-defined schedules via intravenous, intraperitoneal, oral, or intracranial routes as appropriate.
11. Necropsy and Tissue Procurement: At study endpoint, brains are harvested en bloc, photographed, and sectioned coronally; tumor dimensions and vascular architecture are mapped, and tissue aliquots are allocated for formalin-fixed paraffin embedding, snap-freezing, and downstream molecular analysis.
12. Histopathological and Vascular Characterization: Tumor sections undergo H&E staining, IHC for Ki-67, CD31, VEGF, phospho-Akt, cleaved caspase-3, and PLVAP, alongside CD31/PLVAP immunofluorescence to quantify vessel density, fenestration status, and blood-brain barrier integrity within the tumor mass.
13. Data Integration and Reporting: All imaging, survival, biometric, and molecular data are compiled into a comprehensive study report with tumor growth curves, Kaplan-Meier survival analyses, vascular density summaries, neurological scoring trends, and pharmacodynamic interpretations suitable for regulatory or publication use.

Fig 2. U87 Orthotopic Mouse Model construction workflow.

Case Study-U87 Orthotopic Mouse Model Development

In a representative preclinical engagement, the U87 orthotopic glioblastoma model was established in immunodeficient mice with reproducible intracranial tumor take and progressive vascularized growth over a multi-week treatment window. Treatment cohorts receiving a PI3K inhibitor in combination with temozolomide demonstrated enhanced tumor growth inhibition relative to either monotherapy, accompanied by reduced phospho-Akt immunoreactivity and increased cleaved caspase-3 staining in post-treatment tumor sections. A parallel arm evaluating an anti-VEGF receptor antibody showed decreased CD31-positive vessel density and diminished PLVAP expression within the tumor mass, correlating with reduced contrast enhancement on longitudinal MRI. Detailed quantitative datasets—including bioluminescence tumor growth curves, T2-weighted MRI volumetrics, body weight profiles, neurological scoring trends, and vascular density quantification—are available for review; please reach out to our scientific team to discuss how these findings can inform your specific glioblastoma therapeutic strategy.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your U87 orthotopic model program provides access to a vascular and pathway-focused service platform with deep expertise in PTEN-null glioblastoma biology, angiogenesis assessment, and PI3K/Akt-targeted therapeutic evaluation.

• Established proficiency with the classic U87MG human glioblastoma xenograft and optimized stereotactic protocols that yield consistent intracranial engraftment with predictable vascularized, well-circumscribed tumor growth.
• Integrated longitudinal bioluminescence and MRI imaging infrastructure for real-time tracking of tumor burden, peritumoral edema, and early pharmacodynamic readouts.
• Specialized vascular phenotyping capabilities including CD31/PLVAP immunofluorescence, VEGF quantification, and blood-brain barrier permeability assessment to evaluate anti-angiogenic and nanoparticle-delivery strategies.
• Expertise in PI3K/Akt pathway profiling, MGMT methylation status analysis, and p53-wild-type functional assays to dissect mechanism of action in a genetically defined PTEN-null context.
• Flexible study designs supporting monotherapy, combination, sequential, and biomarker-stratified arms tailored to your compound mechanism and regulatory requirements.
• Rigorous cell authentication, health surveillance, and GLP-aligned documentation practices that uphold data integrity for IND-enabling and peer-review standards.

Contact Us

To explore how the U87 orthotopic mouse model can advance your glioblastoma preclinical program, we invite you to reach out to us for a confidential scientific consultation. Our neuro-oncology specialists will evaluate your therapeutic target, propose a customized study design leveraging the unique PTEN-null, MGMT-methylated, and highly vascular features of this classic human glioblastoma xenograft, and outline a clear roadmap to generating the high-quality data your discovery team requires. Contact us today and let Alfa Cytology drive your next preclinical milestone in brain cancer research.

For research use only. Not intended for any clinical use.